Slika na naslovnici

Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective

Background and purpose: Plaque psoriasis is a chronic inflammatory disease with skin manifestations that affect the patients' quality of life negatively. The prevalence of psoriasis is approximately 2-3% worldwide and appears to be still on the increase. Due to the stigma problems, psoriasis ha...

Shranjeno v:

Bibliografske podrobnosti
Main Authors:	Marzieh Zargaran (Author), Fatemeh Soleymani (Author), Saman Ahmad Nasrollahi (Author), Meysam Seyedifar (Author), Mohammad Mehdi Ashrafian Rahaghi (Author)
Format:	Knjiga
Izdano:	Wolters Kluwer Medknow Publications, 2021-01-01T00:00:00Z.
Teme:	article
Online dostop:	Connect to this object online.
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
od: Gisondi P, et al.
Izdano: (2016)

Apremilast and NB-UVB combination therapy in moderate-to-severe plaque type psoriasis
od: O. Yu Olisova, et al.
Izdano: (2020)

Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis
od: Gao JC, et al.
Izdano: (2022)

A Comparative Study of the Efficacy of Methotrexate versus Methotrexate with Apremilast in Moderate to Severe Chronic Plaque Psoriasis
od: Divyanshu Srivastava, et al.
Izdano: (2023)

Real-world insight on apremilast therapy in patients with plaque psoriasis: Indian experience
od: Abhishek De, et al.
Izdano: (2020)

Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States
od: Sang Hee Park, et al.
Izdano: (2024)

Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis
od: April W. Armstrong, et al.
Izdano: (2024)

Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe Psoriasis
od: Bela J Shah, et al.
Izdano: (2020)

Erythrodermic psoriasis treated with apremilast
od: John Arcilla, et al.
Izdano: (2016)

Apremilast for lithium-associated psoriasis
od: Joohyung Youh, et al.
Izdano: (2022)

Treatment of erythrodermic psoriasis with apremilast
od: Olivia A. Gioe, MD, et al.
Izdano: (2021)

Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis
od: Kaplan DL, et al.
Izdano: (2020)

Recurrence of Melanoma after Starting Apremilast for Psoriasis
od: Thomas G. Salopek
Izdano: (2017)

Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study
od: Pablo de laCueva, et al.
Izdano: (2023)

Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents
od: Audrey Melin, et al.
Izdano: (2021)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
od: Light JG, et al.
Izdano: (2021)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
od: Ren V, et al.
Izdano: (2013)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
od: Sekhon S, et al.
Izdano: (2017)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
od: Jin JQ, et al.
Izdano: (2023)

Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
od: Rachael C. Saporito, et al.
Izdano: (2016)

Apremilast in psoriasis and beyond: Big hopes on a small molecule
od: T P Afra, et al.
Izdano: (2019)

Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
od: Forchhammer S, et al.
Izdano: (2015)

Dramatic response of cutaneous, nail, and joint symptoms of psoriasis to apremilast
od: Meghana Bathina, et al.
Izdano: (2019)

The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
od: Rajagopalan M, et al.
Izdano: (2021)

Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting
od: Alessio Gambardella, et al.
Izdano: (2023)

Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis
od: A. A. Kubanov, et al.
Izdano: (2019)

Novel topical therapy for mild-to-moderate plaque psoriasis: focus on calcitriol
od: Lutz Kowalzick
Izdano: (2009)

Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis
od: Giovanna Malara, et al.
Izdano: (2021)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
od: Martina Burlando, et al.
Izdano: (2021)

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
od: Ruggiero A, et al.
Izdano: (2023)

Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series
od: Ander Mayor Ibarguren, MD, et al.
Izdano: (2021)

Psoriasis In Patients With Active Lung Cancer: Is Apremilast a Safe Option?
od: Zoe Apalla, et al.
Izdano: (2019)

Apremilast in people living with HIV with psoriasis vulgaris: A case report
od: Bela J Shah, et al.
Izdano: (2019)

Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study
od: Giovanna Malara, et al.
Izdano: (2021)

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
od: Palfreeman AC, et al.
Izdano: (2013)

Apremilast
od: Nihal Kundakçı
Izdano: (2022)

The Relationship Between Quality Assurance Structure and Profitability in Iranian Pharmaceutical Industries
od: Abbas Kebriaeezade, et al.
Izdano: (2021)

Identification of the Main Elements of Single Payer System; A Comparative Study
od: Ali Aboutorabi, et al.
Izdano: (2019)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
od: Malakouti M, et al.
Izdano: (2016)

Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis
od: Liye XIA, et al.
Izdano: (2024)